SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
____________________________Cytoclonal Pharmaceutics_______________________
(Name of Issuer)
_______________________________Common_Stock___________________________
__
(Title of Class of Securities)
28282G105
________________________________________________________________________
(CUSIP Number)
Bruce Meyers c/o Janssen-Meyers Associates, L.P.
17 State Street, NY, NY 10004 (212) 742-4200
________________________________________________________________________
(Name, Address and Telephone Number Person Authorized to
Receive Notices and Communications)
___________________________________7/1998__________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the
subject of this Schedule 13D, and is filing this schedule because of
Rule 13d-1(b)(3) or (4), check the
following box_____.
Check the following box if a fee is being paid with the statement _____.
(A fee is not required only if the
reporting person: (1) has a previous statement on file reporting
beneficial ownership of more than five
percent of the class of securities described in Item1; and
(2) has filed no amendment subsequent thereto
reporting beneficial ownership of five percent of less of such class.)
(Sec Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should
be filed with the Commission. See Rule
13d-1(a) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with
respect to the subject class of securities, and for any subsequent
amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
1. Name of Reporting Person
_________________Bruce Meyers___________________
S.S. or I.R.S. Identification No. of Above Person
________________________________________________
2. Check the Appropriate Box if a Member of a Group (See
Instructions before filling out)
a.________ b_______
3. SEC USE ONLY
_____________________________________________________
4. Source of Funds (See instructions before filling out).
______________________Personal funds_______________________
5. Check Box if Disclosure of Legal Proceedings is Required Pursuant
to Items
2(d) or 2(e).
_____________________________________________________________________________
6. Citizenship or Place of Organization
_______________________USA__________________________
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
(Questions 7 - 10)
7. Sole Voting Power
___________________________1,186,615_____________________
8. Shared Voting Power
_____________________________________________________
9. Sole Dispositive Power
_________________________1,186,615___________________________
10. Shared Dispositive Power
_____________________________________________________
11. Aggregate Amount Beneficially Owned by Each Reporting Person
_____________________________________________________
12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
(See instructions before filling out)
_____________________________________________________
13. Percent of Class Represented by Amount in Row (11)
_______________________11.73%___________________________
14. Type of Reporting Person (See instructions before filling out)
_______________________Shareholder______________________
